ABSTRACT
Background Chronic airway diseases like cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) pose substantial clinical challenges. This study explores the p.C97W variant in WFDC2, proposed as a new genetic origin of respiratory distress, especially among Koreans.
Methods Whole-exome/genome sequencing (WES/WGS) were performed on 64 patients from 62 families presenting with severe bronchiectasis and chronic rhinosinusitis. In vitro analyses and protein modeling were utilized to evaluate the functional implications of the WFDC2 variant.
Results Pathogenic variants were found in 11.3% of families, including a novel homozygous WFDC2 missense variant (c.291C>G, p.Cys97Trp) in five unrelated families, confirmed by Sanger sequencing. The variant, rare globally but more frequent in Koreans, caused persistent wet cough, chronic rhinosinusitis, and bronchiectasis in affected patients. Lung tissue pathology showed chronic inflammation and interstitial fibrosis. The p.C97W variant impaired WFDC2 protein folding, secretion, and function.
Conclusions The p.C97W variant in WFDC2 is a critical genetic factor in severe chronic airway disease that shares clinical features with CF and PCD. Given its implications for diagnosis and treatment, genetic testing for WFDC2 mutations in individuals with CF or PCD-like symptoms is recommended.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Research Foundation (NRF) grants funded by the Korean government (2018R1A5A2025079 and RS-2023-00261905 to H.Y.G. and the Korea Mouse Phenotyping Project RS-2024-00400118 to H.Y.G.). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2022R1A2C1010462 to K.W.K.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of Severance Hospital, Yonsei University Health System (IRB #4-2013-0770 and #4-2024-0647). Written informed consent was obtained from the patients for their participation in this study and the publication of their clinical data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
